Intranasal hydroxypropyl-β-cyclodextrin-adjuvanted influenza vaccine protects against sub-heterologous virus infection

Kusakabe, Takato; Ozasa, Koji; Kobari, Shingo; Momota, Masatoshi; Kishishita, Natsuko; Kobiyama, Kouji; Kuroda, Etsushi; Ishii, Ken J.

doi:10.1016/j.vaccine.2016.04.001

Cited by 29 publications

(24 citation statements)

References 35 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…For example, it has been established that methylated beta-cyclodextrin can reduce influenza A virus and coronavirus infectivity by sequestering cholesterol from viral particles or depleting it from the host cell membranes [51]. Hydroxypropyl-β-cyclodextrin was used as a vaccine adjuvant providing protection against the H1N1 influenza virus in the cynomolgus monkey model [52,53]. One point to emphasize is that for natural CDs, the intramolecular hydrogen bond with the CD molecule decreases their hydrogen bond formation with the surrounding water molecules [54].…”

Section: Cyclodextrinsmentioning

confidence: 99%

COVID-19: A Recommendation to Examine the Effect of Mouthrinses with β-Cyclodextrin Combined with Citrox in Preventing Infection and Progression

Carrouel

Conte

Fisher

et al. 2020

JCM

130

116

View full text Add to dashboard Cite

Considered to be a major portal of entry for infectious agents, the oral cavity is directly associated with the evolutionary process of SARS-CoV-2 in its inhalation of ambient particles in the air and in expectorations. Some new generations of mouth rinses currently on the market have ingredients that could contribute to lower the SARS-CoV-2 viral load, and thus facilitate the fight against oral transmission. If chlorhexidine, a usual component of mouth rinse, is not efficient to kill SARS-CoV-2, the use of a mouth rinses and/or with local nasal applications that contain β-cyclodextrins combined with flavonoids agents, such as Citrox, could provide valuable adjunctive treatment to reduce the viral load of saliva and nasopharyngeal microbiota, including potential SARS-CoV-2 carriage. We urge national agencies and authorities to start clinical trials to evaluate the preventive effects of βCD-Citrox therapeutic oral biofilm rinses in reducing the viral load of the infection and possibly disease progression.

show abstract

Section: Cyclodextrinsmentioning

confidence: 99%

COVID-19: A Recommendation to Examine the Effect of Mouthrinses with β-Cyclodextrin Combined with Citrox in Preventing Infection and Progression

Carrouel

Conte

Fisher

et al. 2020

JCM

130

116

View full text Add to dashboard Cite

show abstract

“…The synergic effect of HPβCD with immunoglobulins was proven by several previous in vivo studies with mice and macaques, which demonstrated that HPβCD brings a 30% increase in the production of antibodies and that it further induces the production of a subclass of immune cells responsible for long-term immune 'memory'; that is, long-term immunization against the virus [44,45]. It was also demonstrated that the effect of immunization occurs not only at the nasal mucosa, the site of administration, but that it is systemic, spreading throughout the entire body to convey strong immunity to the virus [46]. The vaccine is undergoing phase I clinical studies, which started in October 2017 and continue until the present day [47].…”

Section: Influenza Treatment and Preventionmentioning

confidence: 95%

Cyclodextrins: Emerging Medicines of the New Millennium

2019

View full text Add to dashboard Cite

Cyclodextrins, since their discovery in the late 19th century, were mainly regarded as excipients. Nevertheless, developments in cyclodextrin research have shown that some of these hosts can capture and include biomolecules, highlighting fatty acids and cholesterol, which implies that they are not inert and that their action may be used in specific medicinal purposes. The present review, centered on literature reports from the year 2000 until the present day, presents a comprehensive description of the known biological activities of cyclodextrins and their implications for medicinal applications. The paper is divided into two main sections, one devoted to the properties and applications of cyclodextrins as active pharmaceutical ingredients in a variety of pathologies, from infectious ailments to cardiovascular dysfunctions and metabolic diseases. The second section is dedicated to the use of cyclodextrins in a range of biomedical technologies.

show abstract

“…Forty-one compounds showed protective efficacy similar or superior to that of alum on the basis of survival rates (Table 2). These 41 hit compounds comprised 18 totally novel adjuvant candidates, 15 novel adjuvant candidates for the influenza vaccine with previously reported adjuvant effects for other antigens but not for the influenza vaccine, and 8 previously reported adjuvant candidates for the influenza vaccine (Tables 1 and 2), namely β-cyclodextrin [30,31], poly-L-γ-glutamic acid sodium salt [32,33], polyvinylpyrrolidone (MW 3,600,000) [34], pullulan [35], riboflavin [36], saponin [37][38][39], sepiolite [40], and sodium alginate 80-120 [41] (Table 1, Figure 1, and Table S1). a Six-week-old BALB/c mice were intramuscularly immunized with the indicated immunogens (100 µL) twice at a two-week interval.…”

Section: Identification Of 41 Compounds That Enhance the Protective Ementioning

confidence: 99%

Food Additives as Novel Influenza Vaccine Adjuvants

Feng

Yamashita

et al. 2019

Vaccines

View full text Add to dashboard Cite

Influenza is a major threat to public health. Vaccination is an effective strategy to control influenza; however, the current inactivated influenza vaccine has mild immunogenicity and exhibits suboptimal efficacy in clinical use. Vaccine efficacy can be improved by the addition of adjuvants, but few adjuvants have been approved for human use. To explore novel and effective adjuvants for influenza vaccines, here we screened 145 compounds from food additives approved in Japan. Of these 145 candidates, we identified 41 compounds that enhanced the efficacy of the split influenza hemagglutinin (HA) vaccine against lethal virus challenge in a mouse model. These 41 compounds included 18 novel adjuvant candidates and 15 compounds with previously reported adjuvant effects for other antigens but not for the influenza vaccine. Our results are of value to the development of novel and effective adjuvanted influenza or other vaccines for human use.

show abstract

Intranasal hydroxypropyl-β-cyclodextrin-adjuvanted influenza vaccine protects against sub-heterologous virus infection

Cited by 29 publications

References 35 publications

COVID-19: A Recommendation to Examine the Effect of Mouthrinses with β-Cyclodextrin Combined with Citrox in Preventing Infection and Progression

COVID-19: A Recommendation to Examine the Effect of Mouthrinses with β-Cyclodextrin Combined with Citrox in Preventing Infection and Progression

Cyclodextrins: Emerging Medicines of the New Millennium

Food Additives as Novel Influenza Vaccine Adjuvants

Contact Info

Product

Resources

About